Literature DB >> 26438145

Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group.

Sebastiano Mercadante1,2, Paolo Marchetti3, Arturo Cuomo4, Massimo Mammucari5, Augusto Caraceni6.   

Abstract

Controversies exist about the definition and epidemiology of breakthrough cancer pain (BTcP), the pharmacological treatment options, drug dosing, and how to select the medications for BTcP among the new fentanyl products. Existing data were critically evaluated to provide recommendations by an expert group. An algorithm to diagnose BTcP should be used followed by a careful assessment. Fentanyl products provide efficacy and rapidity of action to counteract the temporal pattern of BTcP. The doses of opioids used for background pain should guide the choice of the doses of fentanyl products. The choice of fentanyl products should be based on individual clinical conditions.

Entities:  

Keywords:  Breakthrough pain; Fentanyl; Morphine; Opioids

Mesh：

Substances：

Year:  2015        PMID： 26438145     DOI： 10.1007/s00520-015-2951-y

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


  42 in total

1.  Development and validation of the breakthrough pain assessment tool (BAT) in cancer patients.

Authors:  Katherine Webber; Andrew N Davies; Giovambattista Zeppetella; Martin R Cowie
Journal:  J Pain Symptom Manage       Date:  2014-04-22       Impact factor: 3.612

2.  Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.

Authors:  Sebastiano Mercadante; Giovanna Prestia; Claudio Adile; Alessandra Casuccio
Journal:  J Pain       Date:  2014-02-19       Impact factor: 5.820

3.  Temporal presentation of chronic cancer pain: transitory pains on admission to a multidisciplinary pain clinic.

Authors:  F Petzke; L Radbruch; D Zech; G Loick; S Grond
Journal:  J Pain Symptom Manage       Date:  1999-06       Impact factor: 3.612

Review 4.  Assessment and classification of cancer breakthrough pain: a systematic literature review.

Authors:  Dagny Faksvåg Haugen; Marianne Jensen Hjermstad; Neil Hagen; Augusto Caraceni; Stein Kaasa
Journal:  Pain       Date:  2010-03-16       Impact factor: 6.961

5.  Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies.

Authors:  Andrew Davies; Giovambattista Zeppetella; Steen Andersen; Anette Damkier; Tove Vejlgaard; Friedemann Nauck; Lukas Radbruch; Karl-Frederik Sjolund; Mariann Stenberg; Alison Buchanan
Journal:  Eur J Pain       Date:  2011-01-19       Impact factor: 3.931

6.  Breakthrough pain: definition, prevalence and characteristics.

Authors:  Russell K Portenoy; Neil A Hagen
Journal:  Pain       Date:  1990-06       Impact factor: 6.961

7.  Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients: results from the Cancer Pain Outcome Research Study Group.

Authors:  Maria Teresa Greco; Oscar Corli; Mauro Montanari; Silvia Deandrea; Vittorina Zagonel; Giovanni Apolone
Journal:  Clin J Pain       Date:  2011-01       Impact factor: 3.442

8.  Breakthrough cancer pain: an observational study of 1000 European oncology patients.

Authors:  Andrew Davies; Alison Buchanan; Giovambattista Zeppetella; Josep Porta-Sales; Rudolf Likar; Wolfgang Weismayr; Ondrej Slama; Tarja Korhonen; Marilene Filbet; Philippe Poulain; Kyriaki Mystakidou; Alexandros Ardavanis; Tony O'Brien; Pauline Wilkinson; Augusto Caraceni; Furio Zucco; Wouter Zuurmond; Steen Andersen; Anette Damkier; Tove Vejlgaard; Friedemann Nauck; Lukas Radbruch; Karl-Fredrik Sjolund; Mariann Stenberg
Journal:  J Pain Symptom Manage       Date:  2013-03-22       Impact factor: 3.612

9.  The Alberta Breakthrough Pain Assessment Tool for cancer patients: a validation study using a delphi process and patient think-aloud interviews.

Authors:  Neil A Hagen; Carla Stiles; Cheryl Nekolaichuk; Patricia Biondo; Linda E Carlson; Kim Fisher; Robin Fainsinger
Journal:  J Pain Symptom Manage       Date:  2008-01-07       Impact factor: 3.612

10.  Episodic (breakthrough) pain prevalence in a population of cancer pain patients. Comparison of clinical diagnoses with the QUDEI--Italian questionnaire for intense episodic pain.

Authors:  Augusto Caraceni; Oscar Bertetto; Roberto Labianca; Marco Maltoni; Sebastiano Mercadante; Giustino Varrassi; Giovanni Zaninetta; Furio Zucco; Michela Bagnasco; Luigi Lanata; Franco De Conno
Journal:  J Pain Symptom Manage       Date:  2012-05       Impact factor: 3.612
View more
  17 in total

1.  Comment on 'What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain: Expert Opinion'.

Authors:  Raffaele Giusti; Lucilla Verna; Daniela Iacono; Agnese Vannini; Corrado Ficorella; Giampiero Porzio
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

2.  The use of low doses of a sublingual fentanyl formulation for breakthrough pain in patients receiving low doses of opioids.

Authors:  Sebastiano Mercadante; Claudio Adile; Arturo Cuomo; Federica Aielli; Franco Marinangeli; Alessandra Casuccio
Journal:  Support Care Cancer       Date:  2016-10-15       Impact factor: 3.603

3.  Fentanyl pectin nasal spray for painful mucositis in head and neck cancers during intensity-modulated radiation therapy with or without chemotherapy.

Authors:  R Mazzola; F Ricchetti; A Fiorentino; N Giaj-Levra; S Fersino; U Tebano; S Albanese; S Gori; F Alongi
Journal:  Clin Transl Oncol       Date:  2016-11-16       Impact factor: 3.405

Review 4.  Opioids for cancer pain - an overview of Cochrane reviews.

Authors:  Philip J Wiffen; Bee Wee; Sheena Derry; Rae F Bell; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2017-07-06

Review 5.  Prostate cancer induced bone pain: pathobiology, current treatments and pain responses from recent clinical trials.

Authors:  A E Smith; A Muralidharan; M T Smith
Journal:  Discov Oncol       Date:  2022-10-18

6.  Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain.

Authors:  Sebastiano Mercadante; Augusto Caraceni; Francesco Masedu; Teresa Scipioni; Federica Aielli
Journal:  Oncologist       Date:  2019-12-20

Review 7.  Episodic Breathlessness in Patients with Advanced Cancer: Characteristics and Management.

Authors:  Sebastiano Mercadante
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

8.  Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS).

Authors:  Sebastiano Mercadante; Paolo Marchetti; Arturo Cuomo; Augusto Caraceni; Rocco Domenico Mediati; Massimo Mammucari; Silvia Natoli; Marzia Lazzari; Mario Dauri; Mario Airoldi; Giuseppe Azzarello; Mauro Bandera; Livio Blasi; Giacomo Cartenì; Bruno Chiurazzi; Benedetta Veruska Pierpaola Costanzo; Daniela Degiovanni; Flavio Fusco; Vittorio Guardamagna; Vincenzo Iaffaioli; Simeone Liguori; Vito Lorusso; Sergio Mameli; Rodolfo Mattioli; Teresita Mazzei; Rita Maria Melotti; Valentino Menardo; Danilo Miotti; Stefano Moroso; Stefano De Santis; Remo Orsetti; Alfonso Papa; Sergio Ricci; Alessandro Fabrizio Sabato; Elvira Scelzi; Michele Sofia; Giuseppe Tonini; Federica Aielli; Alessandro Valle
Journal:  Adv Ther       Date:  2016-11-21       Impact factor: 3.845

9.  The use of fentanyl in pain management in head and neck cancer patients: a narrative review.

Authors:  Raffaele Giusti; Paolo Bossi; Marco Mazzotta; Marco Filetti; Daniela Iacono; Paolo Marchetti
Journal:  Br J Pain       Date:  2017-10-10

10.  Breakthrough Cancer Pain Is Associated with Spinal Gap Junction Activation via Regulation of Connexin 43 in a Mouse Model.

Authors:  Xin Li; Siqing Jiang; Hui Yang; Qian Liao; Shousong Cao; Xuebin Yan; Dong Huang
Journal:  Front Cell Neurosci       Date:  2017-07-17       Impact factor: 5.505
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.